669 related articles for article (PubMed ID: 32127389)
21. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
Tian C; Liu J; Zhou H; Li J; Sun C; Zhu W; Yin Y; Li X
Cancer Lett; 2021 Oct; 518():49-58. PubMed ID: 34139284
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
23. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
24. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.
Xie D; Tian Y; Hu D; Wang Y; Yang Y; Zhou B; Zhang R; Ren Z; Liu M; Xu J; Dong C; Zhao B; Yang L
Signal Transduct Target Ther; 2023 Nov; 8(1):436. PubMed ID: 38016957
[TBL] [Abstract][Full Text] [Related]
26. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
27. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.
Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS
Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860
[TBL] [Abstract][Full Text] [Related]
28. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
29. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
Mei S; Peng S; Vong EG; Zhan J
Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
31. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.
Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH
Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390
[TBL] [Abstract][Full Text] [Related]
32. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL; Bailey D; Zielinski J; Apte A; Musenge F; Karp R; Burke S; Garcon F; Mishra A; Gurumurthy S; Watkins A; Arnold K; Moynihan J; Clancy-Thompson E; Mulgrew K; Adjei G; Deschler K; Potz D; Moody G; Leinster DA; Novick S; Sulikowski M; Bagnall C; Martin P; Lapointe JM; Si H; Morehouse C; Sedic M; Wilkinson RW; Herbst R; Frederick JP; Luheshi N
Clin Cancer Res; 2020 Dec; 26(23):6284-6298. PubMed ID: 32817076
[TBL] [Abstract][Full Text] [Related]
35. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
Wang S; Li Y; Xu C; Dong J; Wei J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
[TBL] [Abstract][Full Text] [Related]
36. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
[TBL] [Abstract][Full Text] [Related]
37. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking.
Tan Z; Chiu MS; Yue M; Kwok HY; Tse MH; Wen Y; Chen B; Yang D; Zhou D; Song YQ; Man K; Chen Z
J Leukoc Biol; 2024 Mar; 115(4):633-646. PubMed ID: 38066571
[TBL] [Abstract][Full Text] [Related]
38. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
[TBL] [Abstract][Full Text] [Related]
39. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
Shibata T; Uchida H; Shiroyama T; Okubo Y; Suzuki T; Ikeda H; Yamaguchi M; Miyagawa Y; Fukuhara T; Cohen JB; Glorioso JC; Watabe T; Hamada H; Tahara H
Gene Ther; 2016 Jun; 23(6):479-88. PubMed ID: 26905369
[TBL] [Abstract][Full Text] [Related]
40. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
